Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05490446 · ClinicalTrials.gov registry record · Phase 2
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
A Phase 2 study of Myelodysplastic Syndromes, sponsored by Agios Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT05490446 is a Phase 2 study of Myelodysplastic Syndromes that is active but no longer recruiting, run by Agios Pharmaceuticals. The registered enrollment target is 87 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05490446, a Phase 2 study of Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Agios Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Conditions Studied
Interventions
- DRUG Tebapivat
Study Locations (20)
Other
- Fakultni nemocnice Ostrava - Ostrava
- CHRU Lille - Lille
- Hôpital Saint Louis - Paris
- University Hospital of Alexandroupolis - Alexandroupoli
California
- Innovative Clinical Research Institute Whittier - Lakewood
- David Geffen School of Medicine at UCLA - Los Angeles
- Emad Ibrahim, MD, Inc. - Redlands
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Florida
- Mayo Clinic Jacksonville - PPDS - Jacksonville
Illinois
- Edward H. Kaplan MD & Associates - Skokie
Missouri
- Washington University School of Medicine - St Louis
New York
- Memorial Sloan Kettering Cancer Center - Long Island City
North Carolina
- Duke Adult Blood and Marrow Clinic - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2029-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05490446
The ClinicalTrials.gov registry entry for NCT05490446 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (69% lower). The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Tebapivat is the first listed.
NCT05490446 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05490446 about?
NCT05490446 is a clinical study titled "A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)". This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
What is the current status of trial NCT05490446?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2022-11-07. Estimated completion is 2029-03.
What conditions does trial NCT05490446 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT05490446?
The interventions under investigation include: Tebapivat (DRUG).
Who is sponsoring clinical trial NCT05490446?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05490446 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.